aktie - 500 Beiträge pro Seite

[pol]

=steigt und steigt- verkaufen oder halten? bitte Meinungen

[XXL_Death]

Weiss ja nicht wann Du eingestiegen bist. Zunächst würde ich versuchen dabei zu bleiben. Du kannst ja mit einem stoploss versuchen das ganze abzusichern und diesen regelmässig nachzuziehen.

Kann natürlich, je nachdem wie knapp Dein stoploss gesetzt ist, passieren das Du bei einer kleineren Korrektur rausfliegst. Bei einer grossen hast Du aber Deine Gewinne gesichert.

Es ist nunmal nicht leicht.

MfG
XXL

[eueropa]

Aviron weiter im Aufwind trotz schlechtem Umfeld.Alles steuert auf die Zulassung von FLUMIST hin.Also dran bleiben und abwarten!!!!
Hier die letzte neue NEWS:AVIRON
RECEIVES $10 MILLION PAYMENT FOR FluMist™ MANUFACTURING
--C.
Boyd Clarke named chairman of Aviron board of directors --
Mountain
View, CA - January 8, 2001 - Aviron
(Nasdaq: AVIR) today announced that it received a $10 million payment from
American Home Products Corporation (NYSE: AHP) to support commercial manufacturing
and inventory build-up of FluMist™ for a potential product launch during
the 2001-2002 influenza season. This payment is an advance for payments AHP
owes Aviron under the companies` global collaboration agreement for FluMist™ .
The U.S. Food
and Drug Administration (FDA) is currently reviewing a Biologics License Application
for FluMist™ seeking marketing approval for the prevention of influenza
in healthy children and healthy adults.
"We are
delighted that our partners at American Home Products have provided their
financial support for FluMist™ to assist in the commercial production
already underway. These manufacturing activities are essential for us to execute
a product launch during the 2001-2002 influenza season if we receive marketing
clearance from the FDA," said C. Boyd Clarke, Aviron president and chief
executive officer.
Aviron also announced
today that Mr. Clarke has been elected chairman of the board of directors.
He succeeds J. Leighton Read, M.D., Aviron`s founder, who will remain on Aviron`s board of directors.
"Boyd Clarke`s
election to chair Aviron`s board reflects our appreciation for the progress
the company has made under his first year of leadership and the confidence
we have in his ability to continue Aviron`s transition into a commercial stage
company," Read said.
Aviron is a biopharmaceutical
company based in Mountain View, California, focused on the prevention of disease
through innovative vaccine technology.
Aviron is a biopharmaceutical
company based in Mountain View, California focused on the prevention of disease
through innovative vaccine technology.